FDA, Amgen Shelve Sensipar Exclusivity Case
By Jeff Overley ( June 5, 2017, 4:38 PM EDT) -- The U.S. Food and Drug Administration and Amgen Inc. on Monday halted litigation in D.C. federal court over denied exclusivity for blockbuster calcium-control drug Sensipar after agreeing to see if the dispute could be ironed out through administrative channels....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.